Breast most cancers is a posh illness with a number of elements concerned in its pathophysiological improvement. genetic mutations of BRCA1, BRCA2 and p53 are among the many most well-studied elements. The position of different genetic elements like altered expression profiles, SNPs within the regulatory areas of various genes or epigenetic elements like promoter methylation and histone modifications are additionally effectively studied however no stable understanding is offered on distinct key gamers triggering malignancy in breast most cancers, (Phosphatase and tensin homolog) PTEN is understood to be an important tumor suppressor because it has been reported to be lacking or abnormally expressed in lots of most cancers cells.
Right here on this have been studied how PTEN is expressed in malignant and benign most cancers cells by investigating its expression profile and mobile location utilizing Immuno-fluorescence microscopy. On the similar time, quantitative research of the circulatory mi-RNAs associated to the downregulation of PTEN, particularly mir-21 and mir-155 have studied additionally. Sixty biopsy samples, forty have been recognized to be malignant and twenty have been benign. It has been discovered that PTEN is generally expressed in benign samples and its usually localized within the cell membrane, whereas in malignant samples the expression degree of PTEN is decrease or absent and it’s translocated to the cytoplasm.
Apparently the quantitative expression of circulatory mir-21 and mir-155 within the blood plasma of the corresponding sufferers confirmed a associated sample with greater expression in malignant samples, subsequently can it is clear that PTEN is within the cross-talk of genetics and epigenetic regulation in regard of the event of malignant breast most cancers. On the similar time, this examine confirms the significance of circulatory miRNAs as a biomarker for early breast most cancers detection.
Transcriptome-wide profiles of round RNA and RNA-binding protein interactions reveal results on round RNA biogenesis and most cancers pathway expression
Background: Round RNAs (circRNAs) are steady, usually extremely expressed RNA transcripts with potential to modulate different regulatory RNAs. Just a few circRNAs have been proven to bind RNA-binding proteins (RBPs); nonetheless, little is understood in regards to the prevalence and distribution of those interactions in several organic contexts.
Strategies: We conduct an in depth display of circRNA-RBP interactions within the ENCODE cell strains HepG2 and Okay562. We profile circRNAs in deep-sequenced whole RNA samples and analyze circRNA-RBP interactions utilizing a big set of eCLIP information with binding websites of 150 RBPs. We validate interactions for choose circRNAs and RBPs by performing RNA immunoprecipitation and functionally characterize our most attention-grabbing candidates by conducting knockdown research adopted by RNA-Seq.
Outcomes: We generate a complete catalog of circRNA-RBP interactions in HepG2 and Okay562 cells. We present that KHSRP binding websites are enriched in flanking introns of circRNAs and that KHSRP depletion impacts circRNA biogenesis. We determine circRNAs which might be extremely lined by RBP binding websites and experimentally validate particular person circRNA-RBP interactions. We present that circCDYL, a extremely expressed circRNA with scientific and useful implications in bladder most cancers, is sort of fully lined with GRWD1 binding websites in HepG2 cells, and that circCDYL depletion counteracts the impact of GRWD1 depletion. Moreover, we verify interactions between circCDYL and RBPs in bladder most cancers cells and exhibit that circCDYL depletion impacts hallmarks of most cancers and perturbs the expression of key most cancers genes, e.g., TP53. Lastly, we present that elevated ranges of circCDYL are related to total survival of bladder most cancers sufferers.
Conclusions: Our examine demonstrates transcriptome-wide and cell-type-specific circRNA-RBP interactions that would play necessary regulatory roles in tumorigenesis.

Circulatory miRNA-155, miRNA-21 target PTEN expression and activity as a factor in breast cancer development
Sudden tumor response to palliative pelvic radiotherapy in mismatch repair-deficient superior prostate most cancers: a case report
Background: Mismatch-repair-deficiency leading to microsatellite instability (MSI) could confer elevated radiosensitivity in regionally superior/metastatic tumors and thus radiotherapy (RT) probably may need a altering position in treating this subset of sufferers, alone or together with checkpoint inhibitors.
Case presentation: We report a 76 year-old Italian male affected person presenting with regionally superior undifferentiated prostate most cancers (LAPC), infiltrating bladder and rectum. Molecular evaluation revealed high-MSI with an altered expression of MSH2 and MSH6 at immunohistochemistry. Two months after 6 chemotherapy cycles with Docetaxel related to an LHRH analogue, a computed tomography scan confirmed steady illness. After palliative RT (30 Gy/10 fractions) directed to the tumor mass with a 3D-conformal setup, a follow-up computed tomography scan at eight weeks revealed a formidable response that remained steady at computed tomography after 9 months, with sustained biochemical response. To our information, that is the primary case of such a sustained response to low dose RT alone in high-MSI LAPC.
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (HRP) |
MBS6244012-01mL |
MyBiosource |
0.1(mL |
EUR 990 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (HRP) |
MBS6244012-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4310 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (PE) |
MBS6244545-01mL |
MyBiosource |
0.1(mL |
EUR 990 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (PE) |
MBS6244545-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4310 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (AP) |
MBS6241881-01mL |
MyBiosource |
0.1(mL |
EUR 990 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (AP) |
MBS6241881-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4310 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (APC) |
MBS6242414-01mL |
MyBiosource |
0.1(mL |
EUR 990 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (APC) |
MBS6242414-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4310 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (FITC) |
MBS6243479-01mL |
MyBiosource |
0.1(mL |
EUR 990 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (FITC) |
MBS6243479-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4310 |
Breast cancer |
BR1008b |
TissueArray |
each |
EUR 306 |
Description: Breast cancer, lymph node metastatic carcinoma and adjacent normal tissue array, including pathology grade, TNM, clinical stage, and ER/PR/Her2 result, 100 cases/100 cores, replacing BR1008a |
Breast cancer |
BR724 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer, adjacent and adjacent normal tissue array, 66 cases/72 cores |
Breast cancer |
BR725 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer, adjacent and adjacent normal tissue array, 68 cases/72 cores |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (Biotin) |
MBS6242946-01mL |
MyBiosource |
0.1(mL |
EUR 990 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (Biotin) |
MBS6242946-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4310 |
pAIB1 | Amplified in breast cancer 1 protein |
AS10-1577 |
Agrisera AB |
100 µl |
EUR 479 |
SNCG (breast cancer-specific protein 1) |
Mab-606071 |
Antagene |
0.1mg |
EUR 240 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 405) |
MBS6245078-01mL |
MyBiosource |
0.1(mL |
EUR 990 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 405) |
MBS6245078-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4310 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 490) |
MBS6245611-01mL |
MyBiosource |
0.1(mL |
EUR 990 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 490) |
MBS6245611-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4310 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 550) |
MBS6246144-01mL |
MyBiosource |
0.1(mL |
EUR 990 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 550) |
MBS6246144-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4310 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 650) |
MBS6246677-01mL |
MyBiosource |
0.1(mL |
EUR 990 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 650) |
MBS6246677-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4310 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 750) |
MBS6247210-01mL |
MyBiosource |
0.1(mL |
EUR 990 |
BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 750) |
MBS6247210-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4310 |
Breast cancer with cancer adjacent breast tissue array |
BC081116e |
TissueArray |
each |
EUR 306 |
Description: Breast cancer with cancer adjacent breast tissue array, including invasive carcinoma of no special type, breast carcinoma with apocrine differentiation and AT tissue,pat hology grade, IHC (ER/PR/Her-2/Ki67) info, TNM/Stage (AJCC 7th edition), 107 cases/110 cores (core size 1.5mm), replacing BC081116d |
Breast cancer type 2 susceptibility protein |
AP81131 |
SAB |
1mg |
EUR 2640 |
|
Breast cancer type 1 susceptibility protein |
AP81321 |
SAB |
1mg |
EUR 2640 |
|
Breast cancer-overexpressed gene 1 protein |
E8M1210-6 |
EnoGene |
100ul |
EUR 275 |
Description: Available in various conjugation types. |
Breast cancer-overexpressed gene 1 protein |
MBS8534541-01mL |
MyBiosource |
0.1mL |
EUR 345 |
Breast cancer-overexpressed gene 1 protein |
MBS8534541-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
Breast cancer-overexpressed gene 1 protein |
MBS8534541-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
Breast cancer-overexpressed gene 1 protein |
MBS8534541-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
Breast cancer-overexpressed gene 1 protein |
MBS8534541-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
Breast Cancer Metastasis Suppressor 1 Protein |
20-abx263402 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
Breast Cancer Metastasis Suppressor 1 Protein |
abx263402-1mg |
Abbexa |
1 mg |
EUR 225 |
Breast Cancer Metastasis Suppressor 1 Protein |
abx263402-2mg |
Abbexa |
2 mg |
EUR 325 |
Breast Cancer Metastasis Suppressor 1 Protein |
abx263402-5mg |
Abbexa |
5 mg |
EUR 1600 |
Breast cancer ANTIESTROGEN resistance 3 protein |
FP-0006 |
Signosis |
Each |
Ask for price |
Breast Cancer Cell Protein 2 (BRCC2) Antibody |
20-abx141388 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
Synuclein, gamma (Synuclein gamma, Gamma Synuclein, SNCG, SNCG Protein, Breast Cancer Specific Gene 1, Breast Cancer Specific Gene 1 Protein, BCSG1, Breast Cancer Specific Protein 1, Persyn, PRSN, Synoretin, SR) |
MBS623085-01mL |
MyBiosource |
0.1mL |
EUR 650 |
Synuclein, gamma (Synuclein gamma, Gamma Synuclein, SNCG, SNCG Protein, Breast Cancer Specific Gene 1, Breast Cancer Specific Gene 1 Protein, BCSG1, Breast Cancer Specific Protein 1, Persyn, PRSN, Synoretin, SR) |
MBS623085-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2780 |
Synuclein, gamma (Synuclein gamma, Gamma Synuclein, SNCG, SNCG Protein, Breast Cancer Specific Gene 1, Breast Cancer Specific Gene 1 Protein, BCSG1, Breast Cancer Specific Protein 1, Persyn, PRSN, Synoretin, SR) |
MBS620047-002mg |
MyBiosource |
0.02mg |
EUR 580 |
Synuclein, gamma (Synuclein gamma, Gamma Synuclein, SNCG, SNCG Protein, Breast Cancer Specific Gene 1, Breast Cancer Specific Gene 1 Protein, BCSG1, Breast Cancer Specific Protein 1, Persyn, PRSN, Synoretin, SR) |
MBS620047-5x002mg |
MyBiosource |
5x0.02mg |
EUR 2470 |
Breast cancer TMA |
BR602 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer TMA, 3 samples have matched cancer adjacent tissue samples, including pathology grade, TNM and clinical stage (reference AJCC 8th version), 57 cases/60 cores (Core Size 1.5mm), recent tear collections |
Breast cancer with matched cancer adjacent breast tissue array |
BR804b |
TissueArray |
each |
EUR 306 |
Description: Breast cancer with matched cancer adjacent breast tissue array, including pathology grade, TNM, clinical stage and IHC markers (ER, PR, Her-2 and Ki67), 40 cases/80 cores, replacing BR804a |
Amplified In Breast Cancer 1 Protein (NCOA3) Antibody |
abx011671-100g |
Abbexa |
100 µg |
Ask for price |
Amplified In Breast Cancer 1 Protein (NCOA3) Antibody |
abx011671-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
Amplified In Breast Cancer 1 Protein (NCOA3) Antibody |
abx011671-10g |
Abbexa |
10 µg |
EUR 362.5 |
Amplified In Breast Cancer 1 Protein (NCOA3) Antibody |
abx011671-200g |
Abbexa |
200 µg |
Ask for price |
Breast Cancer Exosome |
P141-BR |
101Bio |
- |
Ask for price |
SNCG (breast cancer-specific protein 1) Antibody |
BF0110 |
Affbiotech |
200ul |
EUR 540 |
SNCG (breast cancer-specific protein 1) Antibody |
BF0110-100ul |
Affinity Biosciences |
100ul |
EUR 210 |
Description: WB,IHC,ELISA |
SNCG (breast cancer-specific protein 1) Antibody |
BF0110-200ul |
Affinity Biosciences |
200ul |
Ask for price |
Description: WB,IHC,ELISA |
SNCG (breast cancer-specific protein 1) Antibody |
BF0110-50ul |
Affinity Biosciences |
50ul |
EUR 150 |
Description: WB,IHC,ELISA |
SNCG Antibody (breast cancer-specific protein 1) |
E10-20084 |
EnoGene |
100μg/100μl |
EUR 225 |
Description: Available in various conjugation types. |
SNCG Antibody (breast cancer-specific protein 1) |
MBS850341-01mg |
MyBiosource |
0.1mg |
EUR 305 |
SNCG Antibody (breast cancer-specific protein 1) |
MBS850341-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
SNCG Antibody (breast cancer-specific protein 1) |
MBS850341-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
SNCG Antibody (breast cancer-specific protein 1) |
MBS850341-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
SNCG Antibody (breast cancer-specific protein 1) |
MBS850341-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
CA15-3 Cancer Antigen (Breast Cancer) |
MBS651656-50KUnits |
MyBiosource |
50KUnits |
EUR 1890 |
CA15-3 Cancer Antigen (Breast Cancer) |
MBS651656-5x50KUnits |
MyBiosource |
5x50KUnits |
EUR 8345 |
Breast cancer anti-estrogen resistance protein 3 |
AP80733 |
SAB |
1mg |
EUR 2640 |
|
Breast cancer anti-estrogen resistance protein 3 |
AP80942 |
SAB |
1mg |
EUR 2640 |
|
Breast cancer anti-estrogen resistance protein 3 |
AP80994 |
SAB |
1mg |
EUR 2640 |
|
Breast Cancer Anti-Estrogen Resistance 1 Protein |
abx262743-10mg |
Abbexa |
10 mg |
EUR 325 |
Breast Cancer Anti-Estrogen Resistance 1 Protein |
20-abx262743 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
Breast Cancer Anti-Estrogen Resistance 1 Protein |
abx262743-25mg |
Abbexa |
25 mg |
EUR 6575 |
Breast Cancer Anti-Estrogen Resistance 1 Protein |
abx262743-5mg |
Abbexa |
5 mg |
EUR 225 |
Rat Breast Cancer Susceptibility Protein 1 (BRCA1) Protein |
abx065606-100g |
Abbexa |
100 µg |
EUR 662.5 |
Rat Breast Cancer Susceptibility Protein 1 (BRCA1) Protein |
20-abx065606 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
Rat Breast Cancer Susceptibility Protein 1 (BRCA1) Protein |
abx065606-10g |
Abbexa |
10 µg |
EUR 250 |
Rat Breast Cancer Susceptibility Protein 1 (BRCA1) Protein |
abx065606-50g |
Abbexa |
50 µg |
EUR 462.5 |
Rat Breast Cancer Susceptibility Protein 2 (BRCA2) Protein |
abx166163-100g |
Abbexa |
100 µg |
EUR 637.5 |
Rat Breast Cancer Susceptibility Protein 2 (BRCA2) Protein |
20-abx166163 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
Rat Breast Cancer Susceptibility Protein 2 (BRCA2) Protein |
abx166163-10g |
Abbexa |
10 µg |
EUR 237.5 |
Rat Breast Cancer Susceptibility Protein 2 (BRCA2) Protein |
abx166163-50g |
Abbexa |
50 µg |
EUR 437.5 |
Breast cancer with breast tissue array |
BR2085d |
TissueArray |
each |
EUR 546 |
Description: Breast cancer with breast tissue array, including pathology grad, TNM and clinical stage, 188 cases/208 cores, replacing BR2085c |
Breast cancer with breast tissue array |
BR246d |
TissueArray |
each |
EUR 66 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage (reference AJCC 7th version), 12 cases/24 cores, replacing BR246c |
Breast cancer with breast tissue array |
BR482 |
TissueArray |
each |
EUR 198 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 24 cases/48 cores |
Breast cancer with breast tissue array |
BR720 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical satge (reference AJCC 7th version), 72 cases/72 cores |
Breast cancer with breast tissue array |
BC08118a |
TissueArray |
each |
EUR 258 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 100 cases/100 cores (core size 1.0mm), replacing BC08118 |
Breast cancer with breast tissue array |
T087d |
TissueArray |
each |
EUR 66 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T087c |
Breast cancer with breast tissue array |
T088d |
TissueArray |
each |
EUR 66 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T088c |
Breast cancer membrane protein 11 precursor antibody |
22294 |
SAB |
100ul |
EUR 479 |
Breast cancer type 2 susceptibility protein homolog |
AP81066 |
SAB |
1mg |
EUR 2640 |
|
Breast cancer type 1 susceptibility protein homolog |
AP81109 |
SAB |
1mg |
EUR 2640 |
|
Breast cancer type 1 susceptibility protein homolog |
AP81150 |
SAB |
1mg |
EUR 2640 |
|
Breast cancer type 1 susceptibility protein homolog |
AP81239 |
SAB |
1mg |
EUR 2640 |
|
Breast cancer type 1 susceptibility protein homolog |
AP81415 |
SAB |
1mg |
EUR 2640 |
|
Human Breast Cancer Susceptibility Protein ELISA Kit |
MBS3803297-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Human Breast Cancer Susceptibility Protein ELISA Kit |
MBS3803297-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Human Breast Cancer Susceptibility Protein ELISA Kit |
MBS3803297-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Human Breast Cancer Susceptibility Protein ELISA Kit |
MBS3803297-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
Human Breast Cancer Susceptibility Protein 1 (BRCA1) Protein |
abx065605-100g |
Abbexa |
100 µg |
EUR 700 |
Human Breast Cancer Susceptibility Protein 1 (BRCA1) Protein |
20-abx065605 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
Human Breast Cancer Susceptibility Protein 1 (BRCA1) Protein |
abx065605-10g |
Abbexa |
10 µg |
EUR 250 |
Human Breast Cancer Susceptibility Protein 1 (BRCA1) Protein |
abx065605-50g |
Abbexa |
50 µg |
EUR 475 |
Human Breast Cancer Susceptibility Protein 2 (BRCA2) Protein |
abx065607-100g |
Abbexa |
100 µg |
EUR 612.5 |
Human Breast Cancer Susceptibility Protein 2 (BRCA2) Protein |
20-abx065607 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
Human Breast Cancer Susceptibility Protein 2 (BRCA2) Protein |
abx065607-10g |
Abbexa |
10 µg |
EUR 237.5 |
Human Breast Cancer Susceptibility Protein 2 (BRCA2) Protein |
abx065607-50g |
Abbexa |
50 µg |
EUR 425 |
Mouse Breast Cancer Susceptibility Protein 1 (BRCA1) Protein |
abx166161-100g |
Abbexa |
100 µg |
EUR 612.5 |
Mouse Breast Cancer Susceptibility Protein 1 (BRCA1) Protein |
20-abx166161 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
Mouse Breast Cancer Susceptibility Protein 1 (BRCA1) Protein |
abx166161-10g |
Abbexa |
10 µg |
EUR 237.5 |
Mouse Breast Cancer Susceptibility Protein 1 (BRCA1) Protein |
abx166161-50g |
Abbexa |
50 µg |
EUR 425 |
Mouse Breast Cancer Susceptibility Protein 2 (BRCA2) Protein |
abx166162-100g |
Abbexa |
100 µg |
EUR 612.5 |
Mouse Breast Cancer Susceptibility Protein 2 (BRCA2) Protein |
20-abx166162 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
Mouse Breast Cancer Susceptibility Protein 2 (BRCA2) Protein |
abx166162-10g |
Abbexa |
10 µg |
EUR 237.5 |
Mouse Breast Cancer Susceptibility Protein 2 (BRCA2) Protein |
abx166162-50g |
Abbexa |
50 µg |
EUR 425 |
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
abx129675-100l |
Abbexa |
100 µl |
EUR 262.5 |
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
20-abx129675 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
abx129675-1ml |
Abbexa |
1 ml |
EUR 725 |
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
abx129675-200l |
Abbexa |
200 µl |
EUR 337.5 |
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
abx129746-100l |
Abbexa |
100 µl |
EUR 262.5 |
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
20-abx129746 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
abx129746-1ml |
Abbexa |
1 ml |
EUR 725 |
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
abx129746-200l |
Abbexa |
200 µl |
EUR 337.5 |
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
abx130340-100l |
Abbexa |
100 µl |
EUR 275 |
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
20-abx130340 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
abx130340-1ml |
Abbexa |
1 ml |
EUR 775 |
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
abx130340-200l |
Abbexa |
200 µl |
EUR 350 |
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
abx104049-100g |
Abbexa |
100 µg |
EUR 712.5 |
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
20-abx104049 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
abx104049-20g |
Abbexa |
20 µg |
EUR 262.5 |
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
abx104049-50g |
Abbexa |
50 µg |
EUR 325 |
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
abx104050-100g |
Abbexa |
100 µg |
EUR 775 |
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
20-abx104050 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
abx104050-20g |
Abbexa |
20 µg |
EUR 275 |
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
abx104050-50g |
Abbexa |
50 µg |
EUR 350 |
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
20-abx104051 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody |
20-abx175628 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Breast cancer-overexpressed gene 1 protein Antibody |
48092 |
SAB |
100ul |
EUR 429 |
Breast cancer-overexpressed gene 1 protein Antibody |
48092-100ul |
SAB |
100ul |
EUR 399.6 |
Breast cancer-overexpressed gene 1 protein Antibody |
48092-50ul |
SAB |
50ul |
EUR 286.8 |
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
abx171476-100l |
Abbexa |
100 µl |
EUR 750 |
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
20-abx171476 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
abx171476-1ml |
Abbexa |
1 ml |
Ask for price |
Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody |
abx171476-200l |
Abbexa |
200 µl |
Ask for price |
Conclusions: Routine analysis of MSI in sufferers with regionally problematic superior tumors would possibly change therapy technique and therapy purpose on this setting, from a purely palliative strategy to a quasi-curative paradigm.